
    
      OBJECTIVES:

      I. The objective of this study is to describe outcomes associated with prolonged infusion (3
      hours) compared to standard infusion (30 minutes) cefepime (cefepime hydrochloride) among
      patients being treated empirically for febrile neutropenia.

      OUTLINE: Patients are randomized 1 of 2 treatment arms.

      All patients receive cefepime hydrochloride intravenously (IV) over 30 minutes as their first
      dose.

      ARM I: Patients receive cefepime hydrochloride intravenously (IV) over 30 minutes.

      ARM II: Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8
      hours.
    
  